Oramed Pharmaceuticals Inc. (ORMP) Investor Relations Documents

Oramed Pharmaceuticals Inc. (ORMP) investor relations documents from the company's IR site: 1 presentation, 21 press releases; latest deck 2023-12-19. Read in-app with summaries. First-party data.

Corporate Presentation: Oramed Pharmaceuticals is a clinical-stage biotech developing an oral protein delivery platform, currently holding $150.2M in cash and no debt.

Investor relations documents — source: company IR site
PublishedTypeDocument
2026-06-25Press releaseOramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic
2026-06-25Press releaseOramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic
2026-06-17Press releaseOramed Pharmaceuticals to Join Russell 2000® and Russell 3000® Indexes
2026-06-17Press releaseOramed Pharmaceuticals to Join Russell 2000® and Russell 3000® Indexes
2026-01-13Press releaseOramed and Lifeward Announce Strategic Transaction
2026-01-13Press releaseOramed and Lifeward Announce Strategic Transaction
2026-01-07Press releaseOramed Receives $18 Million Payment from Scilex Holdings, Bringing Current Returns to $118 Million; Board Approves Divid
2026-01-07Press releaseOramed Receives $18 Million Payment from Scilex Holdings, Bringing Current Returns to $118 Million; Board Approves Divid
DocumentOramed Reports Fiscal Third Quarter 2025 Financial Results
2025-11-17Press releaseOramed Reports Fiscal Third Quarter 2025 Financial Results
2025-11-17Press releaseORAMED PHARMACEUTICALS INC. DECLARES DIVIDEND DISTRIBUTION OF COMMON STOCK PURCHASE RIGHTS
2025-06-30Press releasehttps://www.prnewswire.com/news-releases/oramed-reports-fiscal-third-quarter-2025-financial-results-302617174.html
2025-06-30Press releasehttps://www.prnewswire.com/news-releases/oramed-reports-fiscal-third-quarter-2025-financial-results-302617174.html
2025-10-23Press releaseOramed Releases Letter to Shareholders, Highlighting Developments in its Oral Insulin Program, Significant Investment Ap
2025-10-23Press releaseOramed Releases Letter to Shareholders, Highlighting Developments in its Oral Insulin Program, Significant Investment Ap
2025-04-28Press releaseOramed Pharmaceuticals Announces $36.9 Million Investment and Strategic Collaboration with Alpha Tau Medical
2025-04-28Press releaseOramed Pharmaceuticals Announces $36.9 Million Investment and Strategic Collaboration with Alpha Tau Medical
2025-03-04Press releaseOramed Pharmaceuticals Issues Letter to Shareholders
2025-03-04Press releaseOramed Pharmaceuticals Issues Letter to Shareholders
2025-02-11Press releaseOramed Announces Transformative Joint Venture to Accelerate Development and Commercialization of Oral Insulin
2025-02-11Press releaseOramed Announces Transformative Joint Venture to Accelerate Development and Commercialization of Oral Insulin
2024-10-07Press releaseOramed Pharmaceuticals Announces Restructuring of Scilex Holding Company Debt
2023-12-19PresentationCorporate Presentation

ORMP overview · ORMP earnings · ORMP financials · ORMP KPIs · ORMP ownership · ORMP peers · ORMP filings

Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.